---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-055819"
form_type: "8-K"
ticker: null
cik: "0000861838"
company_name: "Aceragen, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T23:47:09.549052+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Aceragen lays off ~80% of staff, CFO departs; cash runway only into May 2023; FDA lifts clinical hold on ACG-801

## Summary
- Approximately 80% of employees terminated effective April 28, 2023; expects ~$4.5M restructuring charges in Q2 2023.
- CFO John Kirby departs; CEO John Taylor assumes CFO duties effective immediately.
- Existing cash and equivalents fund operations only into May 2023; needs to raise additional capital.
- FDA lifts clinical hold on ACG-801 for Farber disease, enabling ADVANCE study subject to financing availability.
- Company warns it may need to scale back development, seek a sale, or cease operations if unable to raise capital.

## SEC filing metadata
- accession: 0001104659-23-055819
- form_type: 8-K
- cik: 0000861838
- company_name: Aceragen, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/tm2314659d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-055819
- JSON: https://secwatch.observer/filing/0001104659-23-055819.json
- Plain text: https://secwatch.observer/filing/0001104659-23-055819.txt

## Key facts
- Executive change
  John Taylor changed role as Chief Financial Officer at Aceragen, Inc..
  - Action: assumed duties of Chief Financial Officer
  - Role: Chief Financial Officer
  source text: John Taylor, the Company's Chief Executive Officer, has assumed the duties of Chief Financial Officer of the Company as of the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm
- Executive change
  John Kirby departed as Chief Financial Officer at Aceragen, Inc..
  - Action: no longer serves
  - Role: Chief Financial Officer
  source text: John Kirby no longer serves as the Company's Chief Financial Officer or is employed by the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm
- Restructurings & Charges
  Aceragen, Inc. announced a restructuring with charges of approximately $4.5 million (approximately 80% of the Company’s employees).
  - Type: restructuring
  - Charge: approximately $4.5 million
  - Headcount: approximately 80% of the Company’s employees
  source text: (the “2022 Form 10-K”). In connection with the Reduction, the Company estimates that it will incur aggregate restructuring charges in the second quarter of 2023 of approximately $4.5 million related to severance payments and other employee-related costs. The Company’s estimates are subject to a number of assumptions, and actual results may differ. The Company may
  evidence_url: https://www.sec.gov/Archives/edgar/data/861838/000110465923055819/0001104659-23-055819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.